Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Reports outline gene therapy study findings from University of Tubingen
December 18th, 2008
"The biosynthetic gene cluster of the aminocoumarin antibiotic novobiocin contains two putative regulatory genes, i.e., novE and novG. Functional proof for the role of NovG as a positive regulator of novobiocin biosynthesis had been provided previously, and we now investigated the role of novE," researchers in Tubingen, Germany report. "Heterologous expression experiments with the novobiocin biosynthetic gene cluster showed that the entire putative promoter region of novE is required to achieve optimal novobiocin production. Overexpression of novE, using a replicative vector, resulted in an increase of novobiocin formation. In contrast, inactivation of novE by in frame...
Source: Gene Therapy Weekly (2008-12-18)
|
